UPDATE 2-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs

* Starts next phase of key obesity study next year (Adds comment by CEO, Victoza's market share, R&D spending in obesity)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.